Copyright
©The Author(s) 2020.
World J Clin Cases. Nov 6, 2020; 8(21): 5320-5325
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5320
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5320
Figure 1 Changes in serum potassium and creatinine levels before and during nafamostat mesylate administration.
Serum potassium levels increased in all four patients on the third day of NM administration without acute kidney disease. A: Serum potassium; B: Serum creatinine. Cre: Creatinine; NM: Nafamostat mesylate; K: Potassium.
- Citation: Okajima M, Takahashi Y, Kaji T, Ogawa N, Mouri H. Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports. World J Clin Cases 2020; 8(21): 5320-5325
- URL: https://www.wjgnet.com/2307-8960/full/v8/i21/5320.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i21.5320